ARCTURUS THERAPEUTICS HOLDINGS INC. Operating Expenses
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Operating Expenses of $28.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating expenses for the quarter ending 2026-06-30 was $28.50M, a 28.59% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating expenses for the quarter ending 2026-03-31 was $30.99M, a 32.93% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating expenses for the quarter ending 2025-12-31 was $38.50M, a 31.44% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating expenses for the quarter ending 2025-09-30 was $33.66M, a 35.77% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating expenses for fiscal 2025 was $158.29M, a 36.17% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating expenses for fiscal 2024 was $247.98M, a 1.21% increase from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating expenses for fiscal 2023 was $245.00M, a 26.41% increase from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. operating expenses for fiscal 2022 was $193.82M, a 9.94% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.50M 10-Q · filed 2026-08-06 | $59.50M 10-Q · filed 2026-08-06 | $98.00M derived: sum of 3 quarters · filed 2026-08-06 | $131.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $30.99M 10-Q · filed 2026-05-07 | $69.50M derived: sum of 2 quarters · filed 2026-05-07 | $103.16M derived: sum of 3 quarters · filed 2026-05-07 | $143.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $38.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $72.17M derived: sum of 2 quarters · filed 2026-03-03 | $112.08M derived: sum of 3 quarters · filed 2026-08-06 | $158.29M 10-K · filed 2026-03-03 |
| 2025-09-30 | $33.66M 10-Q · filed 2025-11-12 | $73.58M derived: sum of 2 quarters · filed 2026-08-06 | $119.79M 10-Q · filed 2025-11-12 | $175.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $39.92M 10-Q · filed 2026-08-06 | $86.13M 10-Q · filed 2026-08-06 | $142.28M derived: sum of 3 quarters · filed 2026-08-06 | $194.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $46.21M 10-Q · filed 2026-05-07 | $102.37M derived: sum of 2 quarters · filed 2026-05-07 | $154.78M derived: sum of 3 quarters · filed 2026-05-07 | $225.76M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $56.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $108.57M derived: sum of 2 quarters · filed 2026-03-03 | $179.56M derived: sum of 3 quarters · filed 2026-03-03 | $247.98M 10-K · filed 2026-03-03 |
| 2024-09-30 | $52.41M 10-Q · filed 2025-11-12 | $123.39M derived: sum of 2 quarters · filed 2025-11-12 | $191.82M 10-Q · filed 2025-11-12 | $240.95M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $70.98M 10-Q · filed 2025-08-11 | $139.41M 10-Q · filed 2025-08-11 | $188.54M derived: sum of 3 quarters · filed 2026-03-03 | $252.99M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $68.42M 10-Q · filed 2025-05-12 | $117.55M derived: sum of 2 quarters · filed 2026-03-03 | $182.00M derived: sum of 3 quarters · filed 2026-03-03 | $247.90M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $49.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $113.58M derived: sum of 2 quarters · filed 2026-03-03 | $179.47M derived: sum of 3 quarters · filed 2026-03-03 | $245.00M 10-K · filed 2026-03-03 |
| 2023-09-30 | $64.45M 10-Q · filed 2024-11-07 | $130.35M derived: sum of 2 quarters · filed 2024-11-07 | $195.88M 10-Q · filed 2024-11-07 | $234.72M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $65.89M 10-Q · filed 2024-08-05 | $131.42M 10-Q · filed 2024-08-05 | $170.26M derived: sum of 3 quarters · filed 2025-03-06 | $220.44M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $65.53M 10-Q · filed 2024-05-08 | $104.37M derived: sum of 2 quarters · filed 2025-03-06 | $154.55M derived: sum of 3 quarters · filed 2025-03-06 | $203.73M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $38.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $89.02M derived: sum of 2 quarters · filed 2025-03-06 | $138.20M derived: sum of 3 quarters · filed 2025-03-06 | $193.82M 10-K · filed 2025-03-06 |
| 2022-09-30 | $50.18M 10-Q · filed 2023-11-14 | $99.36M derived: sum of 2 quarters · filed 2023-11-14 | $154.98M 10-Q · filed 2023-11-14 | $198.42M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $49.18M 10-Q · filed 2023-08-07 | $104.81M 10-Q · filed 2023-08-07 | $148.24M derived: sum of 3 quarters · filed 2024-03-14 | $204.50M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $55.62M 10-Q · filed 2023-05-09 | $99.06M derived: sum of 2 quarters · filed 2024-03-14 | $155.32M derived: sum of 3 quarters · filed 2024-03-14 | $211.04M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $43.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $99.70M derived: sum of 2 quarters · filed 2024-03-14 | $155.42M derived: sum of 3 quarters · filed 2024-03-14 | $215.21M 10-K · filed 2024-03-14 |
| 2021-09-30 | $56.26M 10-Q · filed 2022-11-09 | $111.98M derived: sum of 2 quarters · filed 2022-11-09 | $171.77M 10-Q · filed 2022-11-09 | $205.09M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $55.72M 10-Q · filed 2022-08-09 | $115.51M 10-Q · filed 2022-08-09 | $148.83M derived: sum of 3 quarters · filed 2022-08-09 | $172.10M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $59.79M 10-Q · filed 2022-05-09 | $93.11M derived: sum of 2 quarters · filed 2022-05-09 | $116.38M derived: sum of 3 quarters · filed 2022-05-09 | $128.75M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $33.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $56.59M derived: sum of 2 quarters · filed 2022-03-01 | $68.95M derived: sum of 3 quarters · filed 2022-03-01 | $81.06M 10-K · filed 2022-03-01 |
| 2020-09-30 | $23.27M 10-Q · filed 2021-11-09 | $35.63M derived: sum of 2 quarters · filed 2021-11-09 | $47.74M 10-Q · filed 2021-11-09 | $61.53M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $12.36M 10-Q · filed 2021-08-10 | $24.47M 10-Q · filed 2021-08-10 | $38.26M derived: sum of 3 quarters · filed 2022-03-01 | $49.19M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $12.11M 10-Q · filed 2021-05-10 | $25.89M derived: sum of 2 quarters · filed 2022-03-01 | $36.83M derived: sum of 3 quarters · filed 2022-03-01 | $47.55M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $13.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $24.72M derived: sum of 2 quarters · filed 2022-03-01 | $35.44M derived: sum of 3 quarters · filed 2022-03-01 | $46.30M 10-K · filed 2022-03-01 |
| 2019-09-30 | $10.93M 10-Q · filed 2020-11-09 | $21.66M derived: sum of 2 quarters · filed 2020-11-09 | $32.52M 10-Q · filed 2020-11-09 | $40.80M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $10.72M 10-Q · filed 2020-08-10 | $21.58M 10-Q · filed 2020-08-10 | $29.87M derived: sum of 3 quarters · filed 2021-03-01 | $37.65M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $10.86M 10-Q · filed 2020-05-08 | $19.15M derived: sum of 2 quarters · filed 2021-03-01 | $26.93M derived: sum of 3 quarters · filed 2021-03-01 | $39.38M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $8.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $16.07M derived: sum of 2 quarters · filed 2021-03-01 | $28.52M derived: sum of 3 quarters · filed 2021-03-01 | $37.56M 10-K · filed 2021-03-01 |
| 2018-09-30 | $7.78M 10-Q · filed 2019-11-08 | $20.24M derived: sum of 2 quarters · filed 2019-11-08 | $29.28M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $12.46M 10-Q · filed 2019-08-14 | $21.50M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |